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Glycoprotein IV or CD36 forms one of the most abundant glycoproteins on the surface of mouse and human plate-
lets, expressed at ≤25 000 copies per cell.1,2 CD36 consists 
of a double membrane-spanning protein with 1 large extra-
cellular domain and 2 short N- and C-terminal cytoplasmic 
domains.3–5 Its function has remained unclear for long. Earlier, 
CD36 was thought to be a platelet collagen receptor,6,7 but it 
was shown that platelets from CD36-deficient patients have 
an unchanged response to collagen.8,9 Subsequent studies 
suggested a role for CD36 as receptor for thrombospondin-1 
(TSP1).10,11 It was also found that CD36 can bind oxidized 
lipids, including oxidized low-density lipoproteins (oxLDLs), 
particularly at conditions promoting atherogenesis.12,13 Earlier, 
we and other have demonstrated that interaction of CD36 with 
surface- immobilized TSP1 or oxLDL leads to outside-in sig-
naling events in platelets via c-Jun N-terminal kinases (JNK) 
and spleen tyrosine kinase (Syk), and enforced via autocrine 
loops of secreted ADP and P2Y
12
 receptors.14,15 Interestingly, 
this signaling promotes Ca2+-dependent exposure of proco-
agulant phosphatidylserine at the platelet surface.
See accompanying editorial on page 1120
The multidomain matrix glycoprotein TSP1 is one of 
the most highly expressed proteins in platelet α-granules 
(≈101 000 copies per cell).2 TSP1 is also found in the blood 
vessel, likely after deposition secreted by platelets and vas-
cular cells.16–18 In addition to CD36, several other platelet 
receptors for TSP1 have been proposed. These include the 
glycoprotein Ib-V-IX complex19–21 and glycoprotein CD47.22 
TSP1 can also indirectly influence platelet activity via binding 
to collagen, fibrinogen, and von Willebrand factor and protect 
the latter from cleavage by matrix proteinases.23
Lack of platelet α-granules is associated with a mild-to- 
moderate bleeding tendency in patients with the congenital 
gray platelet syndrome.24 The genetic defect has recently been 
attributed to mutations in the neurobeachin-like 2 (NBEAL2) 
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Objective—Platelets abundantly express the membrane receptor CD36 and store its ligand thrombospondin-1 (TSP1) in the 
α-granules. We investigated whether released TSP1 can support platelet adhesion and thrombus formation via interaction 
with CD36.
Approach and Results—Mouse platelets deficient in CD36 showed reduced adhesion to TSP1 and subsequent phosphatidylserine 
expression. Deficiency in either CD36 or TSP1 resulted in markedly increased dissolution of thrombi formed on collagen, 
although thrombus buildup was unchanged. In mesenteric vessels in vivo, deficiency in CD36 prolonged the time to 
occlusion and enhanced embolization, which was in agreement with earlier observations in TSP1-deficient mice. Thrombi 
formed using wild-type blood stained positively for secreted TSP1. Releasate from wild-type but not from  TSP1-
deficient platelets enhanced platelet activation, phosphatidylserine expression, and thrombus formation on collagen. The 
enhancement was dependent on CD36 because it was without effect on thrombus formation by CD36-deficient platelets.
Conclusions—These results demonstrate an anchoring role of platelet-released TSP1 via CD36 in platelet adhesion and 
collagen-dependent thrombus stabilization. Thus, the TSP1–CD36 tandem is another platelet ligand–receptor axis 
contributing to the maintenance of a stable thrombus.  (Arterioscler Thromb Vasc Biol. 2014;34:1187-1192.)
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gene.25,26 In mice, deficiency in Nbeal2 similarly results in 
defective α-granule biogenesis, accompanied by diminished 
platelet adhesion, phosphatidylserine exposure, and thrombus 
formation.27 To date, it has remained unclear which of the pro-
teins stored in platelet α-granules contribute to these responses.
In the present article, we hypothesized that the abundantly 
expressed TSP1, secreted from the α-granules and interacting 
with its counter-receptor CD36, starts an additional autocrine 
feed-forward loop and supports the interactions of platelets in 
a thrombus. This hypothesis was tested using mice deficient 
in either CD36 or TSP1 by assessment of platelet adhesion, 
activation, and thrombus formation.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
In human platelets, CD36 acts as an adhesive receptor for immo-
bilized TSP1.15 To assess this for the mouse system, we measured 
the adhesion of platelets from Cd36+/+ and Cd36−/− mice to surfaces 
coated with purified human TSP1 or a TSP1-containing releasate 
from activated mouse platelets. With either surface, deficiency in 
CD36 resulted in a markedly reduced static adhesion (Figure IA 
in the online-only Data Supplement). Labeling with fluorescein 
isothiocyanate- annexin A5 indicated that the lower adhesion of 
Cd36−/− platelets was accompanied by a lower phosphatidylserine 
exposure, suggesting reduced platelet activation (Figure IB in the 
online-only Data Supplement). Immunofluorescence experiments 
indicated that surface-coated releasate from wild- type platelets 
stained positively for TSP1, whereas surface-coated releasate 
from Tsp1−/− platelets failed to stain (Figure IIA and IIB in the 
online-only Data Supplement). We determined whether phospha-
tidylserine-exposing microparticles as possible CD36 ligands28 
may contribute to the adhesion of platelets to surface- coated 
releasates. However, staining of these coatings with fluorescein 
isothiocyanate-annexin A5 did not result in a detectable fluores-
cence signal, pointing to the absence of microparticles on the 
coated surface (Figure III in the online-only Data Supplement). 
Together, the data indicated that CD36 acts as an adhesive recep-
tor for mouse platelets on released and immobilized TSP1.
To determine the activation tendency of platelets from 




 activation, α-granule 
secretion, and phosphatidylserine exposure in response to 
ADP or a glycoprotein VI agonist, convulxin. No difference 
was observed in any of the responses between the knockout 
and wild-type platelets (Figure IC–IE in the online-only Data 
Supplement). These results are in agreement with our previous 
data that blockage of CD36 does not affect agonist-induced 
activation of suspended human platelets.15 Similarly, other 
authors have described that CD36-deficient mouse platelets in 
suspension are unchanged in activation properties.12,29
Considering that CD36 mediates platelet adhesion to immo-
bilized TSP1, we investigated whether platelet-released TSP1 
contributes to thrombus formation under flow conditions. Whole 
blood from Tsp1−/− or corresponding wild-type mice was per-
fused over collagen at high wall shear rate. Thrombi formed with 
Tsp1−/− and Tsp1+/+ blood differed neither in deposition of plate-





ing with PE-JON/A monoclonal antibody; Figure 1A and 1B). 
However, thrombi formed with Tsp1−/− blood were significantly 
reduced in platelet phosphatidylserine exposure. Immunostaining 
indicated the presence of released TSP1 in wild-type thrombi, 
but not in Tsp1−/− thrombi. To stimulate activation and secretion, 
thrombi on collagen were treated with ADP and then immu-
nostained for TSP1 (Figure 1C and 1D). Strong staining of the 
Tsp1+/+ thrombi was observed, but not of the Tsp1−/− thrombi.
The roles of CD36 and TSP1 in thrombus formation were 
studied using Cd36−/− blood, which was perfused over collagen 
surfaces containing releasate from Tsp1−/− or Tsp1+/+ platelets. 
Control experiments indicated that surfaces with only releas-
ates did not result in adhesion of Cd36+/+ or Cd36−/− platelets 
(Figure 2A and 2B). However, in combination with collagen, 
releasate from Tsp1+/+ platelets but not from Tsp1−/− platelets 
enhanced the process of thrombus formation in perfusions with 
Cd36+/+ blood only (P=0.035). Image analysis indicated that 
mean thrombus size was largest for the combination of Tsp1+/+ 
releasate and Cd36+/+ blood (P=0.001; Figure 2C). When using 
Cd36−/− blood, no increase in thrombus size was observed in 
the presence of releasate from Tsp1+/+ or Tsp1−/− platelets.




 activation did not show marked 
differences between Cd36−/− and Cd36+/+ thrombi formed on 





and phosphatidylserine exposure were significantly increased 
in Cd36+/+ thrombi (P=0.005 and P=0.027, respectively), when 
these were formed on a surface with collagen plus releasate from 
Tsp1+/+ (but not Tsp1−/−) platelets (Figure 3A–3D). Notably, the 
stimulating effect of Tsp1+/+ releasate was absent in Cd36−/− 
thrombi. Together, this pointed to a platelet-activating effect 
of immobilized TSP1 via CD36, thus supporting collagen- 
dependent thrombus formation and procoagulant activity.
Considering that paracrine platelet agents such as ADP, throm-
boxane, and Gas6 contribute to thrombus stabilization,30,31 we 
investigated the stability of thrombi formed with Cd36−/−, Tsp1−/−, 
or wild-type blood. This was done by measuring the rate of dis-
solution of preformed thrombi during a high shear postperfusion 
protocol.30 Strikingly, whereas the wild-type thrombi remained 
stable for a longer period, the thrombi of platelets deficient 
in either CD36 or TSP1 disintegrated within several minutes 
(Figure 4A; see Movies in the online-only Data Supplement). 
Quantification of thrombus dissolution during a 6-minute period 
indicated a significant increase in this parameter for Cd36−/− 
and Tsp1−/− platelets in comparison with wild type (Figure 4B). 
Control experiments pointed out that in Tsp1−/− blood the blocking 
anti-mouse CD36 antibody MAB1258 did not have an additional 
effect (data not shown), suggesting that no other CD36 ligand was 
involved in thrombus stabilization. Furthermore, pretreatment of 
Cd36+/+ or Cd36−/− blood with a blocking antibody against CD47 
did not change platelet deposition or thrombus stability (data not 
shown). Together, these findings pointed to a role of TSP1–CD36 
interaction in the stabilization of thrombi at high shear flow.
To investigate this under in vivo conditions, we measured the 
thrombotic process in mesenteric arterioles and venules from 
Nonstandard Abbreviations and Acronyms
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Cd36+/+ and Cd36−/− mice, injured with FeCl
3
. In the vessels from 
Cd36−/− mice, thrombus formation was delayed and more unsta-
ble, that is, more embolization, in comparison with wild-type mice 
(Figure 5A and Movies in the online-only Data Supplement). This 
resulted in prolonged occlusion times in both the arterioles and 
venules of Cd36−/− mice (Figure 5B). These results are compatible 
Figure 1. Thrombospondin-1 (TSP1) released from platelets during thrombus formation supports phosphatidylserine (PS) exposure. A and B, 
Blood from Tsp1+/+ or Tsp1−/− mice was perfused during 4 minutes over collagen at a wall shear rate of 1000/s. A, Representative brightfield 
and fluorescence images recorded poststaining (bar=25 μm). B, Quantification of covered area of all platelets (platelet deposition); labeling 
with PE-JON/A monoclonal antibody (mAb; αIIbβ3 activation); labeling with AF647-annexin A5 (PS exposure); and staining with biotin anti-TSP1 
mAb followed by AF532-streptavidin (TSP1 stain). C and D, Tsp1+/+ or Tsp1−/− thrombi formed on collagen in the presence of ADP (10 μmol/L), 
staining with biotin anti-TSP1 mAb and AF532-streptavidin. C, Representative images (bar=25 μm). D, Quantification of covered area of TSP1 
stain. Means±SEM. (n=3–4). *P<0.05 vs Tsp1+/+. FITC indicates fluorescein isothiocyanate; and n.s., not significant.
Figure 2. Platelet-derived thrombospondin-1 (TSP1) supports thrombus formation on collagen in a CD36-dependent way. Coverslips 
were coated with releasate (RL) from thrombin-stimulated Tsp1+/+ or Tsp1−/− platelets, collagen alone (coll), or collagen postincubated with 
RL, as indicated. Blood from Cd36+/+ or Cd36−/− mice was perfused during 4 minutes at 1000/s. A, Representative brightfield images of 
thrombi formed after flow (bar, 25 μm). B, Quantification of platelet surface area coverage. C, Morphometric analysis of images for mean 
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with our earlier finding that also in mesenteric vessels of Tsp1−/− 
mice thrombus formation is delayed and accompanied by embo-
lization.23 Together, these data indicate that both CD36 and TSP1 
play a role in thrombus stabilization in vivo.
Discussion
In this study, we hypothesized that platelet-secreted TSP1 
by interacting with CD36 provides an additional autocrine 
feed-forward loop that enforces the interactions of platelets 
in a growing thrombus. The results of this article agree with a 
stimulatory effect of the TSP1–CD36 axis in thrombus forma-
tion and stabilization. Our data indicate that, similarly to puri-
fied human TSP1, the releasate from wild-type but not from 
Tsp1−/− platelets augments platelet adhesion and phosphati-
dylserine exposure in a CD36-dependent way, that is, detect-
able with wild-type but not Cd36−/− platelets. In addition, we 
find that only the releasate from wild-type platelets enhances 
collagen-induced thrombus formation, integrin activation, 
and phosphatidylserine exposure at high shear flow condi-
tions. Furthermore, we find that stable thrombus formation is 
impaired in mice deficient in TSP1 or CD36 both in in vitro 
and in vivo experiments. In vitro, we could establish that the 
impairment was not further increased by blockage of CD36.
Jointly, these results indicate that platelet-derived TSP1 and 
CD36 support adhesion and activation of platelets to phos-
phatidylserine exposure and thrombus stabilization. These are 
considered to be relevant findings because TSP1, although also 
present in the vessel wall, is accumulated within the blood in 
platelet α-granules.2,16,17 The TSP1 that is secreted from activated 
platelets thus may deposit on collagen or a growing thrombus 
and then act in an autocrine way to enforce the thrombus-form-
ing process. Interestingly, the present findings with Cd36−/− and 
Tsp1−/− platelets are reminiscent—although with a less strong 
phenotype—of those published for Nbeal2−/− platelets. These 
platelets (lacking α-granules) show impaired adhesion, reduced 
phosphatidylserine exposure, and diminished thrombus forma-
tion accompanied by increased thrombus instability.27 Hence, 
TSP1 may be one of the α-granular proteins contributing to full 
and stable thrombus formation. This idea is supported by the 
fact that both TSP1 and CD36 are highly expressed in (mouse 
and human) platelets, thus allowing multiple possible interaction 
sites. Likely, also other α-granule–derived proteins than TSP1 
will play a role in thrombus formation, but we like to note that 
TSP1—differently from von Willebrand factor, fibrinogen, and 
Gas6—is mostly stored in the blood in platelets and is present in 
plasma at only low concentrations.
The present results are in agreement with earlier data, 
showing that immobilized TSP1 activates human platelets via 
CD36 through a Syk kinase–dependent mechanism, resulting 




, and exposure 
of phosphatidylserine.15 Also, in endothelial cells, a role for 
TSP1 in signaling via CD36 has been proposed.32 Others have 
Figure 3. Platelet-derived thrombospondin-1 (TSP1) enhances phosphatidylserine exposure in thrombus formation in the presence of 
CD36. Blood from Cd36+/+ or Cd36−/− mice was perfused during 4 minutes at 1000/s over a surface of releasate (RL) from Tsp1+/+ platelets, 
over collagen alone (coll), or collagen postincubated with RL from Tsp1+/+ or Tsp1−/− platelets, as indicated. A and C, Representative fluo-
rescence images (bar, 25 μm) of thrombi stained for activated αIIbβ3 (PE-JON/A monoclonal antibody) and phosphatidylserine exposure 
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provided evidence that TSP1 can promote platelet activation 
via the glycoprotein CD47.22 However, in our experiments, 
blocking CD47 did not influence the process of thrombus 
formation in the presence or absence of CD36. These experi-
ments, however, do not rule out that TSP1 can act by bind-
ing to other platelet ligands in the extracellular space, for 
example, von Willebrand factor and fibrinogen. In the absence 
of TSP1, also other effects may occur, given the previously 
identified role of TSP1 in protecting von Willebrand factor 
from ADAMTS13 (a disintegrin and metalloproteinase with 
a thrombospondin type 1 motif, member 13) degradation.23 
Similarly, in the absence of CD36, also the interaction with 
other ligands, such as oxLDL, will be prevented. In other 
words, although the present results clearly point to an overlap 
of the functions of CD36 and TSP1 in thrombus formation, 
they do not impose that these functions are identical.
Various authors have pointed to a role of either CD36 or TSP1, 
although in a different context and not focusing on the TSP1–
CD36 axis. Platelet CD36, by acting as a scavenging receptor 
of oxLDL, was found to contribute to atherosclerotic lesion 
development33 and hyperlipidemia-associated enhanced platelet 
reactivity.12 The oxLDL–CD36 pathway is supposed to signal via 
the mitogen-activated protein kinases JNK,14 and p38 mitogen-
activated protein kinase,13 and the tyrosine kinase Syk.15
In earlier work, we demonstrated that continued inside-out 
signaling via ADP/ADP receptors and Gas6/Gas6 receptors, as 
well as PEAR1 (platelet endothelial aggregation receptor 1), 




 activation and maintenance of 
platelet–platelet interactions and thereby to stabilization of a 
formed thrombus.30,31,34 The present findings extend this con-
cept by revealing the involvement of another autocrine axis in 
thrombus stabilization, namely the interaction of CD36 with 
platelet-derived TSP1.
Taken together, our results point to defined roles of murine 
CD36 and platelet-derived TSP1 in collagen-dependent 
thrombus formation under high shear flow conditions. Thus, 
TSP1 binding to platelet CD36 can be considered as another 
of the multiple receptor–ligand interactions required for the 
buildup of a stable thrombus.
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Figure 4. Platelet CD36 and thrombospondin-1 (TSP1) support 
thrombus stabilization on collagen. Thrombi were formed by 4 min-
utes perfusion over collagen at 1000/s, using blood from Cd36−/−, 
Tsp1−/−, or corresponding wild-type mice. Stability of thrombi was 
evaluated during 6 minutes of postperfusion with modified Tyrode 
buffer, containing 2 mmol/L CaCl2 and 1 U/mL heparin. A, Repre-
sentative phase-contrast images taken during postperfusion (bar, 
25 μm). B, Dissolution of thrombi during postperfusion calculated 
by subtraction analysis. Representative data of ≥4 experiments. 
See also Movies in the online-only Data Supplement.
Figure 5. Platelet CD36 supports formation of stable thrombi in 
vivo. Thrombus formation was induced in mesenteric vessels from 
Cd36+/+ and Cd36−/− mice by FeCl3 injury. Animals were preinjected 
with rhodamine 6G to fluorescently label circulating cells. A, Rep-
resentative images showing thrombus instability and embolization 
in injured arterioles from Cd36−/− mice. Dotted lines indicate vessel 
walls; right image is 50 seconds later than left image (bar, 100 μm). 
See also Movies in the online-only Data Supplement. B, Distribu-
tion plots of occlusion times in arterioles (top) and venules (bottom) 
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